

Human PD-L1 (epitope 2)

www.mesoscale.com®

Ordering Information

MSD Customer Service
 Phone: 1-240-314-2795
 Fax: 1-301-990-2776
 Email: CustomerService@mesoscale.com

Scientific Support

Phone: 1-240-314-2798
 Email: ScientificSupport@mesoscale.com


Company Address

Meso Scale Discovery, a
 division of Meso Scale
 Diagnostics
 , LLC.
 1601 Research Boulevard
 Rockville, MD 20850-3173 USA

Product Options	Catalog Number	Description
Multiplex	K151AEM, K251AEM	U-PLEX Immuno-Oncology Group 1 (human)
Singleplex	K151AHSK-1/-2/-4	U-PLEX Human PD-L1 (epitope 2) Assay with SECTOR™ plates
	K151AHSK-21/-22/-24	U-PLEX Human PD-L1 (epitope 2) Assay with QuickPlex® plates
	K251AHSK-2/-4	U-PLEX Human PD-L1 (epitope 2) Assay with 384-well plates
Antibody Set	B21AHS-2/-3	U-PLEX Human PD-L1 (epitope 2) Antibody Set
Protocol	U-PLEX Product Inserts are available at www.mesoscale.com .	

The U-PLEX® platform was designed to provide ultimate flexibility for the detection of biomarkers in a wide variety of sample types. This datasheet provides the representative performance of the U-PLEX Human PD-L1 (epitope 2) Assay tested on U-PLEX plates run as a multiplex. The data do not represent the product specifications. Under your experimental conditions, the assay may perform differently from the representative data. U-PLEX assays are offered in either singleplex or multiplex; both are available on 96- or 384-well plates. See a U-PLEX product insert for instrument compatibility.

Representative Calibration Curve and Sensitivity



Assay	Median LLOD (pg/mL)	LLOD Range (pg/mL)
PD-L1 (epitope 2)	0.55	0.39–1.27

The Calibrator curve was fitted with a 4-parameter logistic model with a 1/Y² weighting. The lower limit of detection (LLOD) is a calculated concentration corresponding to 2.5 standard deviations above the background (zero Calibrator).

Precision

Control	Average Conc. (pg/mL)	Average Intra-run Conc. (%CV)	Inter-run Conc. (%CV)
High	194	2.3	5.4
Mid	66	4.1	6.0
Low	25	2.6	8.7

Controls were made by spiking Calibrator into assay diluent at 3 levels within the quantitative range of the assay. Average intra-run concentration %CV is the average %CV of the control replicates within an individual run. Inter-run concentration %CV is the variability of controls across multiple runs.

For Research Use Only.
 Not for use in diagnostic
 procedures.

MSD® U-PLEX Human PD-L1 (epitope 2)

Tested Samples

Sample Type	Serum (N = 9)	EDTA Plasma (N = 9)	Citrate Plasma (N = 9)	Normal Lysate (N = 5)	Tumor Lysate (N = 5)
Median (pg/mL)	47	43	35	7.3	49
Range (pg/mL)	32–101	29–103	22–83	0.08–67	2.3–107
% Detected	100	100	100	60	80

Normal serum and plasma samples were diluted 4-fold prior to the assay. Lysates were tested at a protein concentration of 0.5 mg/mL.

Dilution Linearity

Serum			EDTA Plasma		
Fold Dilution	Average % Recovery	% Recovery Range	Fold Dilution	Average % Recovery	% Recovery Range
2	114	101–119	2	115	99–123
8	91	84–101	8	91	85–102
16	89	82–105	16	89	80–105

Samples were spiked with calibrator and serially diluted. Percent recovery at each dilution was normalized to the dilution-adjusted 4 (or 100)-fold concentration. Samples may benefit from additional dilution with assay diluent to reduce matrix effects.

$$\% \text{ Recovery} = (\text{measured concentration} / \text{expected concentration}) \times 100$$

Spike Recovery

Spike Level	Serum		EDTA Plasma	
	Average % Recovery	% Recovery Range	Average % Recovery	% Recovery Range
High	113	96–126	120	96–128
Mid	115	97–141	122	102–134
Low	113	97–123	120	109–125

Samples were spiked with calibrator at three levels within the range of the assay. Percent recovery was calculated as % Recovery = (measured concentration / (spike + endogenous concentrations)) X 100.

Specificity

To assess specificity, the PD-L1 (epitope 2) Antibody Set was tested individually against a larger panel of analytes for nonspecific binding: APRIL/TNFSF13, BAFF-R/TNFRSF13C, BCMA/TNFRSF17, CD20, CD27, CD276/B7-H3, CD28, CD40L (soluble), CTACK, CTLA-4, ENA-78, Eotaxin, Eotaxin-2, Eotaxin-3, EPO, E-Selectin, FGF (basic), FLT3L, Fractalkine, G-CSF, Galectin-9, GITR/TNFRSF18, GITRL/TNFSF18, GM-CSF, gp130 (soluble), Granzyme A, Granzyme B, GRO- α , HAVCR2/TIM-3, HVEM/TNFRSF14, I-309, ICOS, ICOSL/B7-H2, IFN- α 2a, IFN- β , IFN- γ , IL-1 α , IL-1 β , IL-1RA, IL-10, IL-12/IL-23p40, IL-12p70, IL-13, IL-15, IL-16, IL-17A, IL-17A/F, IL-17C, IL-17D, IL-17E/IL-25, IL-17F, IL-18, IL-2, IL-21, IL-22, IL-23, IL-27, IL-29/IFN- λ 1, IL-2R α , IL-3, IL-31, IL-33, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IP-10, I-TAC, LAG-3, LIGHT/TNFSF14, MCP-1, MCP-2, MCP-4, M-CSF, MDC, MIF, MIG, MIP-1 α , MIP-5, MMP-1, MMP-2, MMP-7, MMP-9, Nectin-4, OX40/TNFRSF4, PD1, PD-L1, PD-L2, Pentraxin 3, Perforin, PIGF, P-Selectin, RAGE (soluble), RANKL/TNFSF11, RANTES, S100A12, TARC, Tie-2, TIGIT, TLR-1, TNF-RI, TNF-RII, TNF- α , TNF- β , TPO, TRAIL, TSLP, VEGF-A, VEGF-D, VEGFR-1/Flt-1 and YKL-40. Nonspecific binding was less than 2.0%.

$$\% \text{ Nonspecificity} = (\text{nonspecific signal} / \text{specific signal}) \times 100$$

The PD-L1 (epitope 2) assay will cross-react with the PD-L1 (epitope 1). We do not recommend multiplexing the PD-L1 (epitope 2) assay with the PD-L1 (epitope 1) assay.

Diluent Compatibility

Diluents 58 and 3 are provided with this assay. MSD offers a range of assay and antibody diluents for separate purchase. Depending on your assay needs, other diluents may be tested.

Assay Components

Calibrator: PD-L1 (epitope 2) is included in Calibrator 21. The human PD-L1 (epitope 2) Calibrator is a full-length recombinant protein expressed in a human cell line.

Antibodies: The U-PLEX Human PD-L1 (epitope 2) Assay uses a mouse monoclonal antibody for capture and a mouse monoclonal antibody for detection.

Assay generation: A

Note: This datasheet contains representative assay performance data. In custom multiplex formats, the assay may perform differently from the representative data shown.

